MedTrace Logo

Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

NCT04476459 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2021-03-15

No results posted yet for this study

Summary

This study will evaluate the efficacy and safety of camrelizumab in combination with apatinib in in patients with relapsed or refractory diffuse large B cell lymphoma failed from second line chemotherapy.

Conditions

  • Diffuse Large B Cell Lymphoma
  • High-grade B-cell Lymphoma
  • Follicular Lymphoma Grade IIIb
  • Transformed Lymphoma
  • EBV-Positive DLBCL, Nos
  • ALK-Positive Anaplastic Large Cell Lymphoma

Interventions

DRUG

Camrelizumab

Camrelizumab will be administered every 3 weeks up to 6 cycles during induction phase, and then every 4 weeks up to 12 cycles in maintenance phase if patients get CR or PR after induction phase.

DRUG

Apatinib

Phase I: dose escalation phase. Patients will oral dosage as 250mg, 500mg or 750mg,qd, per day. Aim to evaluate MTD and DLT, RP2D. Phase II：Patients continuous oral apatinib as RP2D up to 6 cycles during induction phase, and then 250mg/d up to 1 year in maintenance phase if patients get CR or PR after induction phase.

Sponsors & Collaborators

  • Huiqiang Huang

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-23
Primary Completion
2022-08-01
Completion
2023-08-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04476459 on ClinicalTrials.gov